title: Targeting of beta adrenergic receptors results in therapeutic efficacy against models of hemangioendothelioma and angiosarcoma.
abstract: Therapeutic targeting of the beta-adrenergic receptors has recently shown remarkable efficacy in the treatment of benign vascular tumors such as infantile hemangiomas. As infantile hemangiomas are reported to express high levels of beta adrenergic receptors, we examined the expression of these receptors on more aggressive vascular tumors such as hemangioendotheliomas and angiosarcomas, revealing beta 1, 2, and 3 receptors were indeed present and therefore aggressive vascular tumors may similarly show increased susceptibility to the inhibitory effects of beta blockade. Using a panel of hemangioendothelioma and angiosarcoma cell lines, we demonstrate that beta adrenergic inhibition blocks cell proliferation and induces apoptosis in a dose dependent manner. Beta blockade is selective for vascular tumor cells over normal endothelial cells and synergistically effective when combined with standard chemotherapeutic or cytotoxic agents. We demonstrate that inhibition of beta adrenergic signaling induces large scale changes in the global gene expression patterns of vascular tumors, including alterations in the expression of established cell cycle and apoptotic regulators. Using in vivo tumor models we demonstrate that beta blockade shows remarkable efficacy as a single agent in reducing the growth of angiosarcoma tumors. In summary, these experiments demonstrate the selective cytotoxicity and tumor suppressive ability of beta adrenergic inhibition on malignant vascular tumors and have laid the groundwork for a promising treatment of angiosarcomas in humans.
authors.affiliation: Department of Biomedical Sciences, Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA.
authors.forename: Jessica M
authors.initials: JM
authors.lastname: Stiles
authors.forename: Clarissa
authors.initials: C
authors.lastname: Amaya
authors.forename: Steven
authors.initials: S
authors.lastname: Rains
authors.forename: Dolores
authors.initials: D
authors.lastname: Diaz
authors.forename: Robert
authors.initials: R
authors.lastname: Pham
authors.forename: James
authors.initials: J
authors.lastname: Battiste
authors.forename: Jaime F
authors.initials: JF
authors.lastname: Modiano
authors.forename: Victor
authors.initials: V
authors.lastname: Kokta
authors.forename: Laura E
authors.initials: LE
authors.lastname: Boucheron
authors.forename: Dianne C
authors.initials: DC
authors.lastname: Mitchell
authors.forename: Brad A
authors.initials: BA
authors.lastname: Bryan
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D015153:Blotting, Western; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D003599:Cytoskeleton / Q000378:metabolism; D005260:Female; D005455:Fluorescent Antibody Technique; D006390:Hemangioendothelioma / Q000188:drug therapy* / Q000378:metabolism*; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use*; D011943:Receptors, Adrenergic, beta / Q000378:metabolism*
chemical_list: D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D011433:Propranolol
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3154-60
references.pmid: 19451429
references.citation: Curr Oncol Rep. 2002 Nov;4(6):515-9
references.pmid: 12354365
references.citation: J Surg Oncol. 2008 Nov 1;98(6):432-7
references.pmid: 18792957
references.citation: J Pediatr Hematol Oncol. 2011 May;33(4):e171-3
references.pmid: 21516018
references.citation: Breast Cancer Res Treat. 2011 Nov;130(2):457-63
references.pmid: 21298476
references.citation: Br J Pharmacol. 2012 May;166(2):721-36
references.pmid: 22122228
references.citation: Exp Ther Med. 2012 Oct;4(4):594-604
references.pmid: 23170111
references.citation: Oncotarget. 2010 Nov;1(7):628-38
references.pmid: 21317458
references.citation: Pediatr Blood Cancer. 2012 Nov;59(5):934-8
references.pmid: 22648868
references.citation: Biochem Soc Trans. 2011 Dec;39(6):1592-6
references.pmid: 22103492
references.citation: Recenti Prog Med. 2012 Jan;103(1):11-6
references.pmid: 22322621
references.citation: Cytometry A. 2003 Jul;54(1):8-18
references.pmid: 12820116
references.citation: Cancer Res. 2010 Sep 15;70(18):7042-52
references.pmid: 20823155
references.citation: Breast Cancer Res Treat. 2000 Mar;60(2):153-66
references.pmid: 10845278
references.citation: J Clin Oncol. 2009 Jul 1;27(19):3133-40
references.pmid: 19451436
references.citation: Am J Surg Pathol. 1997 Apr;21(4):363-74
references.pmid: 9130982
references.citation: Mol Med. 2002 Sep;8(9):551-8
references.pmid: 12456994
references.citation: N Engl J Med. 2008 Jun 12;358(24):2649-51
references.pmid: 18550886
references.citation: PLoS One. 2009 May 20;4(5):e5549
references.pmid: 19461996
references.citation: Jpn J Cancer Res. 2002 Jul;93(7):729-35
references.pmid: 12149137
references.citation: Eksp Onkol. 1984;6(6):50-3
references.pmid: 6441701
references.citation: Int J Cancer. 2006 Jun 1;118(11):2744-9
references.pmid: 16381019
references.citation: Oncotarget. 2011 Oct;2(10):797-809
references.pmid: 22006582
references.citation: J Immunol. 2010 Mar 1;184(5):2449-57
references.pmid: 20124103
references.citation: Cutan Ocul Toxicol. 2011 Sep;30(3):245-8
references.pmid: 21338243
references.citation: Cancer J. 2005 May-Jun;11(3):241-7
references.pmid: 16053668
references.citation: Pediatr Blood Cancer. 2010 Dec 15;55(7):1433-4
references.pmid: 20981697
references.citation: Curr Opin Oncol. 2010 Jul;22(4):351-5
references.pmid: 20485168
references.citation: PLoS Biol. 2012 Jul;10(7):e1001363
references.pmid: 22815651
references.citation: Anticancer Res. 2012 May;32(5):2133-8
references.pmid: 22593501
references.citation: Int J Oncol. 2010 Nov;37(5):1297-305
references.pmid: 20878077
references.citation: J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):e17-20
references.pmid: 22331019
references.citation: Mod Pathol. 2012 Nov;25(11):1446-51
references.pmid: 22743651